Complex presentation for those of you that like to have a deep dive into the biology and clonal dynamics of resistance.
Presentation on Mechanisms of resistance to ta... - CLL Support
Presentation on Mechanisms of resistance to targeted therapies in CLL - an EHA slide presentation
Written by
Jm954
Administrator
To view profiles and participate in discussions please or .
1 Reply
•
Looks like you still have all the best books Jackie,
A well-presented and concise summary. So far I have made it half way to where it starts to get deep, and It appears that the primary point is that mutations influence resistance.
I'll be back for more, or until a cure is found.
JM
Not what you're looking for?
You may also like...
Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies
This has been a banner year for developments in the treatment of CLL. In this last week of 2015 on...
Comparative analysis of targeted novel therapies (ibrutinib vs. venetoclax) in relapsed, refractory CLL (Feb 2020)
"To date, no prospective trials have directly compared ibrutinib with venetoclax as NA1 in R/R CLL....
EHA 2016: Professor Hallek on the Unmet Needs in CLL
Today in the 2016 Conference Coverage section of the CLL Society website, we’ve posted an interview...
Expert Perspective on Key Trial Updates in Treatment of CLL: What You Need to Know From ASCO/EHA/ICML 2021
17th Sept 21
"George Follows, a UK CLL expert, provides his thoughts on updated data from key...
Clonal Evolution, mutations and resistance to CLL treatment
When someone is diagnosed with CLL they have at least one clone of B lymphocytes that are growing...
Related Posts
- Resistance-Associated Mutations in CLL Patients Treated With Novel Agents
- Zanubrutinib looks promising on all fronts in first interim analysis of ALPINE Trial - Ibrutinib v Zanubrutinib in R/R CLL - report from EHA
Dr Michael Keating's Story - Taking CLL Therapies From Bedside to Community
New to CLL in Canada
The Impact of Diet on CLL
